|
Name |
2-Methyl-3-isopropenylcyclohexanol
|
| Molecular Formula | C10H18O | |
| IUPAC Name* |
2-methyl-3-prop-1-en-2-ylcyclohexan-1-ol
|
|
| SMILES |
CC1C(CCCC1O)C(=C)C
|
|
| InChI |
InChI=1S/C10H18O/c1-7(2)9-5-4-6-10(11)8(9)3/h8-11H,1,4-6H2,2-3H3
|
|
| InChIKey |
SUUUWNRRRLQUSP-UHFFFAOYSA-N
|
|
| Synonyms |
SCHEMBL12166658; 2-Methyl-3-isopropenylcyclohexanol; 3-Isopropenyl-2-methylcyclohexanol #; Cyclohexanol, 2-methyl-3-(1-methylethenyl)-, (1.alpha.,2.alpha.,3.alpha.)-
|
|
| CAS | NA | |
| PubChem CID | 557883 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Molecular Weight: | 154.25 | ALogp: | 3.0 |
| HBD: | 1 | HBA: | 1 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 20.2 | Aromatic Rings: | 1 |
| Heavy Atoms: | 11 | QED Weighted: | 0.575 |
| Caco-2 Permeability: | -4.323 | MDCK Permeability: | 0.00001940 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.003 |
| Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.022 |
| 30% Bioavailability (F30%): | 0.014 |
| Blood-Brain-Barrier Penetration (BBB): | 0.97 | Plasma Protein Binding (PPB): | 48.71% |
| Volume Distribution (VD): | 1.206 | Fu: | 40.42% |
| CYP1A2-inhibitor: | 0.153 | CYP1A2-substrate: | 0.812 |
| CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.851 |
| CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.695 |
| CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.857 |
| CYP3A4-inhibitor: | 0.02 | CYP3A4-substrate: | 0.348 |
| Clearance (CL): | 13.397 | Half-life (T1/2): | 0.289 |
| hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.219 |
| Drug-inuced Liver Injury (DILI): | 0.043 | AMES Toxicity: | 0.022 |
| Rat Oral Acute Toxicity: | 0.067 | Maximum Recommended Daily Dose: | 0.076 |
| Skin Sensitization: | 0.115 | Carcinogencity: | 0.275 |
| Eye Corrosion: | 0.099 | Eye Irritation: | 0.798 |
| Respiratory Toxicity: | 0.687 |